Poster – Dose Optimization of Ragistomig (ABL503/TJ-L14B), a PD-L1x 4-1BBBispecific Antibody (Form 6-K)

NovaBridge Biosciences published this content on October 23, 2026, and is solely responsible for the information contained herein. Distributed via EDGAR on October 23, 2026 at 13:15 UTC. If you believe the information included in the content is inaccurate or outdated and requires editing or removal, please contact us at [email protected]